Stefanie Bailey
Psychiatric/Mental Health · Milwaukee, WINPI 1619328069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,225 and has fallen 50.2% since, to $610 in 2025.
Across 119 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$487
- Almatica Pharma LLC$475
- Otsuka America Pharmaceutical, Inc.$402
- Takeda Pharmaceuticals U.S.A., Inc.$339
- Neurocrine Biosciences, Inc.$269
- Axsome Therapeutics, Inc.$248
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,636100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$938
- VRAYLAR$328
- REXULTI$250
- INGREZZA$250
- Auvelity$248
- ARISTADA INITIO$234
- INVEGA SUSTENNA$113
How this compares
$3,638 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $178,417 |
| VraylarCariprazine Hcl | 24 | $38,036 |
| TrintellixVortioxetine Hydrobromide | 16 | $8,246 |
| Lisdexamfetamine Dimesylate | 18 | $6,753 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,214 |
| Vilazodone Hcl | 38 | $4,199 |
| Bupropion XlBupropion Hcl | 120 | $2,969 |
| Aripiprazole | 58 | $2,965 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 51 | $2,906 |
| Lamotrigine | 131 | $2,054 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 57 | $2,028 |
| Quetiapine Fumarate | 84 | $1,972 |
| Hydroxyzine Hcl | 71 | $1,650 |
| Lurasidone Hcl | 27 | $1,201 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $1,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $269 | $178,41721 claims |
| AbbVieVraylar | $487 | $38,03624 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $339 | $12,46127 claims |
| Almatica Pharma LLCSertraline Hcl | $475 | $78590 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Milwaukee
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Ngozi ObioraMilwaukee$19K
- Victoria McGinleyMilwaukee$9K
- Andrea MitchellMilwaukee$6K
- Angeline VercauterenMilwaukee$6K
- Lisa CwiklaMilwaukee$5K
- Julia JasterMilwaukee$5K
- Angelia Felton-WilksMilwaukee$4K
- Kristen AndersonMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.